CClinicalTrials.gg
CompletedNCT02150122Updated Mar 2, 2016

Dietary Requirement for Vitamin D in Adolescents Aged 14-18 Years

An interventional study of Vitamin D3 in Serum 25-hydroxyvitamin D Concentrations (25OHD), sponsored by University of Surrey. Completed at 1 site in United Kingdom. Open to participants aged 14 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-03-02.

Sponsored by University of Surrey · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
14 Years to 18 Years
Sex
All
01

Study summary

It is known that low vitamin D status is a very common problem in the UK. It is also known that a lack of vitamin D availability has potentially serious health implications, especially with respect to bone and muscle function. Much research has recently taken place to establish the vitamin D requirements of key population groups (i.e. pregnant women, the elderly, ethnic minorities). However few data are available describing the vitamin D requirements for male and female adolescents. The period of adolescence is a key stage of growth and development - poor nutrition during this time can have detrimental health consequences for a lifetime.

No intervention studies have comprehensively investigated the vitamin D requirements of adolescents. The proposed ODIN Study will enable a better understanding of how adolescents respond to vitamin D supplementation and the most effective daily amount that will raise and maintain vitamin D status in adolescents during the winter-time. In addition, investigations into the mechanisms of action with respect to any differences observed across the doses of vitamin D and between the genders of the participants will also provide key information. Mechanisms of action will focus on genetic differences as well as differences in vitamin D metabolising enzymes.

The results obtained from this significant study will not only inform the European Food Standards Agency (EFSA) with respect to their imminent deliberations regarding vitamin D recommendations. The ODIN Study will also inform the UK Department of Health's Scientific Advisory Committee on Nutrition (SACN), the wider scientific community and be a critical resource for key stakeholders (i.e. food industry, government health agencies) to collaborate in determining future public health strategies, thus potentially positively impacting on the health of the population for years to come.

The investigators propose that the daily supplementation of 10µg/day (400 IU) and 20µg/day (800 IU) of vitamin D3 for five months will meet the vitamin D requirements of males and females aged 14-18 year and will be sufficient to maintain winter-time 25OHD levels above a range of thresholds between 30 and 50nmol/l.

02

Conditions studied

  • Serum 25-hydroxyvitamin D Concentrations (25OHD)

Keywords

  • Vitamin D
  • Serum 25-hydroxyvitamin D (25OHD)
  • Adolescents
03

In context

Lead sponsor

University of Surrey is the lead sponsor of 90 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Male or female
  • Aged between 14 and 18 years
  • Caucasian ethnicity
  • In good health
  • Written informed consent from the adolescent (and parent if required)

Exclusion criteria

Exclusion Criteria:

  • Currently receiving treatment for medical conditions likely to affect vitamin D metabolism
  • Hypercalcaemia (>2.5mmol/l)
  • Regular use of sun-beds
  • Having a sun holiday one month prior to commencing the trial or plans for a sun holiday within the study period.
  • Use of vitamin supplements containing vitamin D - if the prospective participant agrees to stop vitamin D supplementation to join the study, a wash-out period of 8 weeks prior to commencing the trial would be acceptable.
  • Excessive consumption of alcohol (>14 units per week for females, >21 units per week for males)
  • Smoking >10 cigarettes per day
  • Those following a weight-reducing diet or under dietary restriction (except vegetarianism)
  • Known intolerance/allergy to the constituent ingredients of the daily supplement
  • Clinically significant haematological abnormalities other than mild anaemia (Hb\<12.0g/dl)
  • Active malignancy
  • Pregnant or planning a pregnancy during the study period.
  • Breast-feeding mothers
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    10 micrograms (400 IU) vitamin D3

    Participants will be given a daily supplement containing 10 micrograms (400 IU) vitamin D3 to take for 5 months.

    Dietary Supplement: Vitamin D3

  • Experimental
    20 micrograms (800 IU) vitamin D3

    Participants will be given a daily supplement containing 20 micrograms (800 IU) vitamin D3 to take for 5 months.

    Dietary Supplement: Vitamin D3

  • No intervention
    Placebo

    Participants will be given a placebo, similar in appearance to the vitamin D3 tablets, to take for 5 months.

Interventions

  • Dietary supplementVitamin D3
06

What researchers measure

Primary outcomes

  1. Serum 25-hydroxyvitamin D concentrations

    To investigate the vitamin D intakes needed to maintain serum 25-hydroxyvitamin D (25OHD) concentrations above the deficiency and insufficiency cut off thresholds (30nmol/l and 50nmol/l respectively) in male and female adolescents during the winter time.

    Time frame: Baseline and after 5 months of supplementation

Other outcomes

  1. Identification of genetic polymorphisms for vitamin D

    To investigate the mechanisms (genetic/enzymatic) underlying the differences observed in the preceding objective via genotyping the participants for polymorphisms related to vitamin D metabolism. Secondary analyses will include evaluation of variations in the response to supplementation by single SNP variations and by the genetic vitamin D risk score. To determine, through transcriptomic (global mRNA) analysis of leukocyte samples, genome-wide differences in gene expression, in the adolescents in response to the vitamin D3 supplementation.

    Time frame: Baseline and after 5 months of supplementation

  2. Family links in vitamin D levels and bone health

    To determine the bone mineral density and vitamin D levels (in addition to the assessment of related blood markers and lifestyle factors) of the mothers of the adolescent participants, in order to establish possible familial links in the factors that affect vitamin D status and bone health.

    Time frame: Baseline

07

Study locations

1 site
  • University of Surrey
    Guildford, Surrey GU2 7XH, United Kingdom
08

References and documents

Publications

  • Smith TJ, Tripkovic L, Hauger H, Damsgaard CT, Molgaard C, Lanham-New SA, Hart KH. Winter Cholecalciferol Supplementation at 51 degrees N Has No Effect on Markers of Cardiometabolic Risk in Healthy Adolescents Aged 14-18 Years. J Nutr. 2018 Aug 1;148(8):1269-1275. doi: 10.1093/jn/nxy079. PubMed 29920594 ↗
  • Smith TJ, Tripkovic L, Damsgaard CT, Molgaard C, Ritz C, Wilson-Barnes SL, Dowling KG, Hennessy A, Cashman KD, Kiely M, Lanham-New SA, Hart KH. Estimation of the dietary requirement for vitamin D in adolescents aged 14-18 y: a dose-response, double-blind, randomized placebo-controlled trial. Am J Clin Nutr. 2016 Nov;104(5):1301-1309. doi: 10.3945/ajcn.116.138065. Epub 2016 Sep 21. PubMed 27655438 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02150122
Lead sponsor
University of Surrey
Responsible party
Sponsor
First posted
May 29, 2014
Start date
Oct 2014
Primary completion
Mar 2015
Completion
Mar 2015
Last update
Mar 2, 2016

Study contacts

Susan Lanham-New, Professor
principal investigator · University of Surrey
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion